Novo Nordisk ’s Tresiba minimises hypoglycaemia rate in diabetes trial
Denmark-based pharmaceutical firm Novo Nordisk has reported positive results from a clinical trial (DEVOTE) of Tresiba (insulin degludec) to treat patients with type 2 diabetes.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Clinical Trials | Denmark Health | Diabetes | Diabetes Type 2 | Endocrinology | Insulin | Pharmaceuticals